| |
||
|
Catalogue Number |
Product | Order number / Unit |
| |
||
| 99381 | PSMA I&T |
Please inquire for customized filling and bulk quantities. 
|
|
Precursor for radiometal-labelled PSMA I&T
|
||
| PSMA: prostate-specific membrane antigen | ||
| Molar Mass:1498.37 | ||
| C63H92IN11O23 | ||
| [2192281-54-0] (net peptide) | ||
| Colourless to off-white solid packaged in plastic vials | ||
| Purity: > 95 % | ||
|
Certificates:
CoA; MS (identity); HPLC (purity) |
||
|
Sequence: Glu-CO-Lys[(Sub)DLys-DPhe-DTyr(3I)-DOTAGA] trifluoroacetate |
||
|
Literature: Baum R.P. et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J. Nucl. Med. 2016, 57, 1006-1013. |
||
| Eiber M. et al. Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. J. Nucl. Med., 2016, 57(supplement 2): p. 61-61. | ||
| Schottelius M. et al. [111In] PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res. 2015, 5, 68. | ||
| date of product catalogue issue: 27 February 2019 | ||